---

Background and Objective: Due to high mortality and morbidity of the cervical cancer we decided to compare benefits and advers effects of Gemcitabine plus conventional chemoradiation with conventional chemoradiation with cisplatin alone in Imam Hossein hospital, in Tehran, Iran. Materials and Methods: This double blind clinical trial, was carried out on 34 patients with documented cervical carcinoma during 2006-07 the patients divided into two sub groups: (A)Conventional concurrent chemoradiation with cisplatin(N=18) versus(B) concurrent chemoradiation with cisplatin plus gemicitabine (N=16). The patients with clinical stage of IB2-IVA and normal cell blood count with normal renal and liver function tests included in the study. Irradiation was delivered to all patients through external and internal beams with same dose and schedule. The patients followed for 3 months at least. Clinical response rate and adverse events included Neutropenin, Thrombocytopenia, anemia, diarrhea, nausea, and vomiting compared in two groups with fisher exact test, and t-test. Results: Despite increasing of complete response rate with adding gemcitabine to conventional treatment(81.2% vs. 66.7%), the difference in two groups was not statistically significant. Conclusion: This study indicated that the addition of gemicatabine to conventional chemoradiation with cisplatinrevealed no significant benefits. All adverse events in combination chemotherapy group were greater than conventional treatment.

---

Background and Objective: Squamous carcinoma accounts for the majority of esophageal carcinoma worldwide. This study was done to evaluate the survival rate of patients with esophageal cancer in Iran.

Methods: This historical cohort study was carried outon 105 patients with esophageal squamous cell carcinoma whom admitted to Firoozgar hospital in Tehran, Iran during 2009-14. Patients with esophageal squamous cell carcinoma were treated with chemoradiation either with or without surgery.

Results: The mean age of patients was 63 years. Frequency of esophageal cancer in both sexes in the age group 51-60 years was higher than other groups. 5-year survival in patients with esophageal cancer treated with chemoradiation without surgery was 9.5% and in patients treated with chemoradiation with surgery was 31.7 % (P<0.05). One-year, three-year and five-year survival rate in patients were treated with chemoradiation with or without surgery was 68.5%, 38% and 22.8%, respectively.

Conclusion: The survival rate of patients with esophageal cancer is very low, but the treatment with chemoradiation with surgery can increase life expectancy of patients.